MeridianResearch
← Research notes

Mechanisms 2026-04-15 · 2 min read

Tesamorelin: the GHRH analog with a clinical paper trail

Tesamorelin is the rare research peptide with phase 3 human data behind it. Its structure, pharmacology, and how it compares to sermorelin and CJC-1295.

Tesamorelin is a stabilized analog of human growth-hormone-releasing hormone, GHRH(1-44), and is among the comparatively few research peptides with a published phase 3 clinical record. This note covers its structure, the GHRH-receptor pharmacology that drives the pulsatile GH/IGF-1 axis, the clinical questions investigated in published trials, and analytical identity considerations for the material.

A stabilized GHRH(1-44) analog

Native GHRH(1-44) is rapidly inactivated in plasma, with cleavage at the N-terminus by dipeptidyl peptidase being a primary route of degradation. Tesamorelin carries an N-terminal modification, a trans-3-hexenoyl group, that confers resistance to this proteolysis while retaining the full 44-residue sequence. The result is a longer-lived analog whose pharmacology mirrors that of endogenous GHRH.

GHRH-receptor agonism

The GHRH receptor is a class B G-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. Agonism couples to Gs, raises intracellular cAMP, and stimulates synthesis and secretion of growth hormone. As an agonist of this receptor, tesamorelin acts upstream of the pituitary rather than supplying growth hormone directly, working through the body's own secretory machinery.

Driving the pulsatile GH/IGF-1 axis

A defining feature of GHRH-receptor agonism is that it preserves the pulsatile, feedback-regulated character of the GH axis. Stimulated growth-hormone release acts on peripheral tissues, principally the liver, to raise insulin-like growth factor 1 (IGF-1), which in turn exerts negative feedback at the hypothalamus and pituitary. This retained feedback loop is a key distinction researchers draw between a secretagogue and exogenous growth hormone.

What the published clinical trials investigated

Published clinical investigations, including phase 3 trials, studied tesamorelin in the context of HIV-associated lipodystrophy, with reported endpoints centered on changes in visceral adipose tissue measured by imaging and on circulating IGF-1 as a pharmacodynamic marker of axis activation. These reports are most useful at the level of endpoint categories and direction of effect rather than specific values.

Analytical identity considerations

For laboratory characterization, identity confirmation distinguishes the 44-residue modified sequence from shorter GHRH fragments such as the 1-29 species, since both share an N-terminal region. LC-MS confirmation of the intact molecular weight, including the mass contribution of the hexenoyl modification, together with HPLC purity and peptide mapping, supports unambiguous identity assignment.

These materials are for laboratory research use only and are not for human or veterinary use.

Intended use:
For laboratory research use only.
Prohibited use:
Not for human or veterinary use.